Industry reports
Editor highlights

Search inside this page

Publishers

  • All
    • Global Data

All regions

Free Market Research Guides to Download

Pharmaceutical Analysis & Statistics, April 2014

You might be interested in: therapeutics, cancer, drug, more »

» Purchase Premium Reports

1-30 of about 8 200 reports
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...

  • Industries : Drug and Medication
  • Countries : World
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as ...

  • Industries : Drug and Medication
  • Countries : World
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, Europe
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017 Summary With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the ...

  • Industries : Pathology
  • Countries : United States, World, Europe, Spain, Italy, France, Germany
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update Summary GlobalData has released its new Opportunity Analyzer report, “Oppo ...

  • Industries : Therapy
  • Countries : United States, World
OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018 Summary Autism Spectrum Disorders (ASD) is a chronically underserved market currently dominated by the two approved ...

  • Industries : Drug and Medication
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : Canada
PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : China
PharmaPoint: Crohn's Disease - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - US Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - US Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : Japan
PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds ...

  • Industries : Drug and Medication
  • Countries : India
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...

  • Industries : Drug and Medication
  • Countries : Japan
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...

  • Industries : Drug and Medication
  • Countries : Canada
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : United States
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • April 2014
  • by Global Data

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023 Summary Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • March 2014
  • by Global Data

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022 Summary Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, ...

  • Industries : Pathology
  • Countries : World, United States, Japan, Europe, Sweden, Spain, Italy, France, Germany, Finland
EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • February 2014
  • by Global Data

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one of ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan
EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • February 2014
  • by Global Data

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following ...

  • Industries : Pathology
  • Countries : World, Japan, United States, Spain, Italy, France, Germany
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe

» Read our Company Profiles

About 200 Companies

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

Novartis Inc.

Switzerland

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.